Abstract
Cardiovascular diseases represent a relevant problem worldwide. Data from World Health Organization (W.H.O.) demonstrate that they are one of the principle causes of death: 30% of all losses of human life throughout the world are due to heart diseases. Such data buries a substantial economic cost considering both the direct component, first of all the national health expense, and the indirect part, such as absenteeism rate, productivity loss, quality of life and, more generally, social costs. The future scenario pictured by the W.H.O. reveals a negative trend due to an increasing in the rate of morbidity and mortality especially in Emerging Countries. One of the solution to stem the costs – economic and not – connected to cardiovascular diseases is to empower the prevention activities overall the actions of primary prevention. This require a change in the traditional patient-physician relationship management model to get to an organizational model centred on patient and based on a proactive approach. In this perspective in the paper will be analysed the principal changes that occurred in the Italian national healthcare system and in particular the strategic plans and actions in theme of cardiovascular prevention.
Keywords: Prevention costs, organizational change, patient oriented model, disease management, cardiovascular risk assessment
Current Pharmaceutical Design
Title: Cardiovascular Disease: An Economical Perspective
Volume: 15 Issue: 10
Author(s): A. Lazzini and S. Lazzini
Affiliation:
Keywords: Prevention costs, organizational change, patient oriented model, disease management, cardiovascular risk assessment
Abstract: Cardiovascular diseases represent a relevant problem worldwide. Data from World Health Organization (W.H.O.) demonstrate that they are one of the principle causes of death: 30% of all losses of human life throughout the world are due to heart diseases. Such data buries a substantial economic cost considering both the direct component, first of all the national health expense, and the indirect part, such as absenteeism rate, productivity loss, quality of life and, more generally, social costs. The future scenario pictured by the W.H.O. reveals a negative trend due to an increasing in the rate of morbidity and mortality especially in Emerging Countries. One of the solution to stem the costs – economic and not – connected to cardiovascular diseases is to empower the prevention activities overall the actions of primary prevention. This require a change in the traditional patient-physician relationship management model to get to an organizational model centred on patient and based on a proactive approach. In this perspective in the paper will be analysed the principal changes that occurred in the Italian national healthcare system and in particular the strategic plans and actions in theme of cardiovascular prevention.
Export Options
About this article
Cite this article as:
Lazzini A. and Lazzini S., Cardiovascular Disease: An Economical Perspective, Current Pharmaceutical Design 2009; 15 (10) . https://dx.doi.org/10.2174/138161209787846883
DOI https://dx.doi.org/10.2174/138161209787846883 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inhibitory Effect of Copper on Cystathionine β-Synthase Activity: Protective Effect of an Analog of the Human Albumin N-Terminus
Protein & Peptide Letters ATP-Sensitive Potassium Channels
Current Pharmaceutical Design Injecting Illicit Substances Epidemic and Infective Endocarditis
Infectious Disorders - Drug Targets Emerging Roles for Vasoactive Peptides in Diagnostic and Therapeutic Strategies Against Atherosclerotic Cardiovascular Diseases
Current Protein & Peptide Science Atrial Fibrillation with a Focus on Oral Antiarrhythmic Therapy
Current Drug Therapy Erythropoietin: New Horizon in Cardiovascular Medicine
Recent Patents on Cardiovascular Drug Discovery Closed-loop Neuropharmacology for Epilepsy: Distant Dream or Future Reality?
Current Neuropharmacology Diabetic Vasculopathy and the Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 (LOX-1)
Current Diabetes Reviews Angiogenesis and the Heart
Recent Patents on Cardiovascular Drug Discovery Cholesterol Ester Transfer Protein (CETP), Postprandial Lipemia and Hypolipidemic Drugs
Current Medicinal Chemistry Drug and Medical Device Interactions: Stent Thrombosis and Personalizing Clopidogrel Therapy
Current Pharmacogenomics and Personalized Medicine Left Ventricular Hypertrophy in Isolated Aortic Stenosis: Primetime for the Ventricle
Current Pharmaceutical Biotechnology Editorial: Liraglutide and Cardiometabolic Effects: More than Just Another Antiobesity Drug?
Current Vascular Pharmacology Transforming Mutations of Jak3 (A573V and M511I) Show Differential Sensitivity to Selective Jak3 Inhibitors
Clinical Cancer Drugs Genetics of Atherosclerosis in Murine Models
Current Drug Targets The Potential of Natural Products as Effective Treatments for Allergic Inflammation: Implications for Allergic Rhinitis
Current Topics in Medicinal Chemistry Primary Antiphospholipid Syndrome and Pulmonary Hypertension
Current Pharmaceutical Design Editorial (Thematic Issue: Vitamin D Supplementation: Its Relevance to Obesity, Atopic Dermatitis and Depression)
Current Nutrition & Food Science “The Future Magic Bullet”: A Review of Pharmacological Activities of Ethyl Pyruvate and its Derivatives
Current Drug Therapy Mechanisms Linking Leptin to Arterial and Venous Thrombosis: Potential Pharmacological Targets
Current Pharmaceutical Design